P4A sponsors World Orphan Drug Congress USA 2019
The P4A team will be involved in three main segments of WODC:
· Sophie Schmitz, Managing Partner will be moderating a keynote panel on April 11 at 9:40-10:30am EST on 'Advancing Cell and Gene Therapy: Considerations in manufacturing, R&D expertise, early payer engagement and continuous patient centricity'. She will be joined by a panel of experts from across the cell and gene therapy (CGT) industry including Sandy Macrae, President and Chief Executive Officer, Sangamo Therapeutics;
· Later, on April 11 at 12:40, Sophie will discuss the access perspectives of cell and gene therapy in a presentation titled, '3 pillars of a sustainable CGT world – everything you need to know from a pricing, reimbursement and access perspective'
· Christina Poschen, Consultant will lead a roundtable discussion on April 12 at 14:30 about 'Gene therapy commercial readiness - how to get yourself commercially ready for gene therapy'. This roundtable will seek to understand the practicalities of access agreements, concierge services and technology stewardship
Apart from the speaking engagements, Partners4Access will also be exhibiting their CGT based solutions services on Booth #818, Aparna Krishnan, Director will as usual be on site to podcast from the event.
At the three-day event, P4A's Joanna Fernandes, Senior Analyst will also be supporting the team.
Highlighting the importance of WODC USA in the annual industry conference calendar, Sophie Schmitz said: "This is a significant event for us to sponsor as cell and gene therapies gain prominence with over 1000 ongoing clinical trials and about 800 products in development. This market is expected to reach $5.2 billion in sales by 2026. The US will be a major contributor to this growth and as specialists in CGT, Partners4Access is rightly positioned to offer our unique commercialization solutions."
WODC USA organized by Terrapinn brings together a global gathering of 1,200 leaders in orphan drugs from 50 countries, featuring over 135 presentations covering all aspects of orphan drug development, market access, advocacy and rare disease research. For more details, please visit the Terrapinn website here (https://www.terrapinn.com/
Partners4Access are experts in orphan drug, cell and gene therapy access, partnering with the biotechnology industry to support launches worldwide. Our services focus on five key areas: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence.
As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access. Through various media initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please visit P4A's website: www.partners4access.com or email at firstname.lastname@example.org.